31 May 2008 - GlaxoSmithKline announced the results of two Phase II trials demonstrating the potential for pazopanib, an oral, investigational angiogenesis inhibitor, as a treatment for non-small cell lung cancer (NSCLC), [1] the most common form of lung cancer, [2] and renal cell carcinoma (RCC). [3] The data were presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Pazopanib is not approved in any market for any indication at this time. Pazopanib targets vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR) and c-kit, key proteins that help with the growth of new blood vessels in the body. [4] This process, known as angiogenesis, plays a critical role in the growth and spread of tumors. [5]... GlaxoSmithKline's Press Release -
